It appears to reduce the levels of the plaques, but only slows progression of the disease; it does not cure Alzheimer’s, the company said. Biogen stocks have jumped as much as 42 percent, to $318, …
More Biogen Prepares to Resubmit Request for FDA Approval of Alzheimer’s Drug Videos